Stockreport

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 [Yahoo! Finance]

Gain Therapeutics, Inc.  (GANX) 
PDF baseline with a reduction following 90 days of dosing with GT-02287 in individuals with high baseline CSF glucosylsphingosine Additional MDS-UPDRS data demonstrate con [Read more]